Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report
• The company says it received FDA clearance in September 2025, and that US reimbursement of US$650.50 per scan was confirmed shortly afterwards.
•Revenuerose 9.2 per cent to $1,295.4 million, underlying EBITDA climbed 19.6 per cent to $165.3 million, and underlying net profit after tax increased 41.8 per cent to $52.4 million.
• Underlying net profit after tax (NPAT) slipped 2% to $631 million.
• Ampol expects fourth-quarter output of petrol, diesel and jet fuel to be about 150 ML lower than previously anticipated.
• The group'sAll-In Sustaining Cost(AISC) was A$2,805 per gold-equivalent ounce, which the company said sits below its full-year guidance range.
• Normalised fullyDiluted Earnings per Sharewere 117.9 cents, up 11.6%.
• Life Sciences covers food, pharmaceutical, environmental and related testing, and accounted for about 61 per cent of groupRevenuein FY26.
• A separate temporary supplemental tax, previously expected to end in 2026, would be extended at a lower take.
• PlatformAssetsunder management rose to A$93.6 billion from A$92.7 billion at the end of the second quarter.
• Sales were a record US$2,140.2 million, up 6.8 per cent, with organic constant-currency growth of 5.0 per cent.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…